Industry Hosted Symposiums
Wednesday, 11 August 2021
Hosted and supported by Nevro
Time: 8.00am - 9.00am
Cost: No cost to attend. This session will be available for attendees on the Virtual Attendee Hub
Title: High-frequency spinal cord stimulation for painful diabetic neuropathy: A fireside chat on data and considerations in the Australian context
Chair: Professor Stephen Twigg is an Endocrinologist and Medical Head of Endocrinology Research Laboratories, Royal Prince Alfred Hospital, and Associate Professor, University of Sydney, New South Wales
Speaker/s:
Dr Lea Sorensen, Senior Lecturer, Teaching Specialist Clinical Practitioner College of Nursing and Health Sciences at Flinders University.
Dr Lisa Brooks, Nevro Principal Clinical Research Scientist, United States.
Summary:
Painful diabetic neuropathy (PDN) is estimated to affect around one in five people with diabetes. Despite its prevalence, treatments remain non-specific and often ineffective or intolerable for many patients. Recently the SENZA-PDN prospective, multicenter randomised, controlled clinical trial (RCT) examined whether 10-kHz spinal cord stimulation (SCS) improves outcomes for patients with refractory PDN. The study examined 216 patients 1:1 to 10 kHz SCS (Nevro Corp.) plus conventional medical management (CMM) or CMM alone. Patients had PDN symptoms ≥12 months, lower limb pain ≥5 cm (10 cm visual analogue scale), and haemoglobin A1c ≤10%. Outcomes included pain, neurological function, and quality of life over 12 months. Patients could opt to crossover to the alternative treatment at 6 months. Baseline characteristics were similar between groups. At 6 months, 82% of the CMM group crossed over to SCS treatment and none in the 10 kHz SCS group crossed over to CMM. In total, 154 patients underwent SCS implant; 5 (3.2%) were explanted for infection. At 6 months, there were clear benefits of 10 kHz SCS in lower limb pain, pain interference with daily living, sleep quality, and activity. Most patients treated with 10 kHz SCS also showed improvement on neurological examination. Join the panellists as they discuss the results of the largest RCT to date of SCS management of PDN and what it could mean for patients in Australia.
Thursday, 12 August 2021
Hosted and supported by Abbott
Time: 8.00am - 9.00am
Cost: No cost to attend. This session will be available for attendees on the Virtual Attendee Hub
Title:Meet the next generation of sensor-based glucose monitoring: FreeStyle Libre 2
Chair: TBC
Speaker/s:
Dr Emma Wilmot (UK), Professor Steven Twigg, Associate Professor Margaret McGill
Summary:
Abbott is excited to introduce to you the next generation sensor-based glucose monitoring: FreeStyle Libre 2, bringing you all the features you already love from FreeStyle Libre and more!
Join our Breakfast Symposium to learn more about FreeStyle Libre 2.
Hosted and supported by Novo Nordisk
Time: 8.00am - 9.00am
Cost: No cost to attend. This session will be available for attendees on the Virtual Attendee Hub
Title: Getting to target: where do GLP-1RAs fit into T2D management?
Chair: TBC
Speaker/s:
Kerry Porter Nurse Practitioner, Credentialled Diabetes Educator, Nurse Lead of Diabetes & Endocrinology services, Queensland Health
Dr Tom Dover Endocrinologist, Queensland Health; Exercise Physiologist, Dietitian
Dr Kate Haigh Endocrinologist, Rhythm Endocrinology & Diabetes; Associate Lecturer, University of Queensland
Summary:
Recent updates to both local and international treatment guidelines support the use of glucagon like peptide-1 receptor agonists (GLP-1RAs) as a second line option after metformin therapy in individuals with type 2 diabetes, highlighting the clinical utility of this class early in the treatment of this disease.
Hear from an expert panel of speakers including endocrinologists Dr Tom Dover, Dr Kate Haigh and credentialled diabetes educator Kerry Porter as they discuss why GLP-1RAs are a suitable treatment option across the T2D treatment spectrum. Join the live panel discussion on how to optimise the clinical use of GLP-1RAs and submit your questions to the speakers. Real-life case studies with the once-weekly GLP-1RA Ozempic® (semaglutide) will be discussed along with practical considerations for the broad use of this medication for managing T2D.
References:
- Buse JB et al. Diabetologia 2020;63:221–228.
- Davies MJ et al. Diabetologia 2018;61:2461-2498.
- Australia Diabetes Society T2D guidelines - http://t2d.diabetessociety.com.au/plan/ Accessed July 2021
- Novo Nordisk. Ozempic® (semaglutide) Product Information. Available at: https://www.novonordisk.com.au
Hosted and supported by Insulet Australia
Time: 8.00am - 9.00am
Cost: No cost to attend. This session will be available for attendees on the Virtual Attendee Hub
Title: Simplifying Insulin Delivery with Omnipod DASH® System
Who, What & Why?
Chair: Jo Sader – Country Manager Insulet Omnipod
Speaker/s:
Dr Trang Ly - Medical Director & VP Insulet. Title: Increasing Adoption to Diabetes Technology by Utilising the Omnipod DASH® System
Prof David O’Neal. Title: Omnipod DASH® System – The Australian Perspective
Tannya and Anna Stevens. Title : The Podder™ Experience
Friday, 13 August 2021
Hosted and supported by Novo Nordisk
Time: 8.00am - 9.00am
Cost: No cost to attend. This session will be available for attendees on the Virtual Attendee Hub
Title: Ryzodeg®(IdegAsp) 3 years on – Real world evidence and clinical consensus”
Chair: Dr. Anthony Roberts, MBBS, FRACP, Medical Co-ordinator of Thyroid and Parathyroid Clinic | Royal Adelaide Hospital, Principal Investigator | SA Endocrine Research Pty Ltd
Speaker/s:
Professor Greg R Fulcher, OAM.MB.BS.MD.FRACP, Clinical Director Chronic and Complex Medicine NSLHD, Senior Staff Specialist Royal North Shore Hospital, Clinical Professor of Medicine, University of Sydney
A/Prof Sarah Glastras, B Psych (Hons) MBBS (Hons) FRACP PhD, Staff Specialist in Endocrinology | Royal North Shore Hospital, Conjoint Associate Professor | University of Sydney
Summary:
Ryzodeg® is a co-formulation of insulin degludec and insulin aspart (IDegAsp), which provides both prandial and basal glycaemic coverage without the need for multiple injections. The efficacy and safety profile of Ryzodeg® has been demonstrated in people with T2D in randomised, controlled, treat-to-target clinical trials and in this symposium we investigate the clinical parameters in a real-world population of patients with T2D who have initiated or switched to IDegAsp from previous anti-hyperglycaemic treatment according to local clinical practice in six selected countries. Implications of this data on current clinical practice and alignment with current consensus and guidelines is also examined.